ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / GENB / options
ZBIO (38) AGIO (35) TRAX (44) ADRX (48) ⌘ Pro Terminal →

Generate Biomedicines Inc. (GENB) Options Positioning, Max Pain & Unusual Sweeps

$13.21 -8.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.98

Generate Biomedicines Inc. (GENB) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.86B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GENB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GENB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Generate Biomedicines Inc. (NASDAQ: GENB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $13.21 (-8.64% 1D, market cap $1.86B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GENB compare to ZBIO and AGIO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GENB carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ZBIO (Zenas BioPharma Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B) and AGIO (Agios Pharmaceuticals Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -33.8%, cap $1.82B). Among the 5-stock peer group, GENB leads on earnings multiple (N/A) while AGIO leads on capital efficiency (-33.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GENB?
▼

Per GENB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002100782), Generate Biomedicines Inc. generated $138.7M in revenue, $0 in net income, and $0 in free cash flow against $330.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $12.98 (-1.75%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 37.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510052
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C
Cash (10)Whales (8)SEC (13)Macro (12)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-2.7% Base Target
$24 Bull$13 Base$10 Bear
📬 FREE GENB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GENB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (52/100 Composite)
🔍 WHY GENB SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (23% of score)

FRED Regime × Technicals: 19% of 52W Range • RSI-14 at 51.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$12.26+5.2% Next Q
Q2 (-2Q)
47
Grade D$12.90+2.4% Next Q
Q3 (-1Q)
49
Grade D$13.21+0% Next Q
Current
52
Grade D+$13.21-1.1% Hist 90D α
Trajectory: D (44) → D+ (52)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GENB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GENB currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.92) and Max Pain ($13.87) forces dealer call-delta covering toward $23.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GENB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GENB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 52%NO 48%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (GENB)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for GENB.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GENB)

  • ✓Walkthrough of GENB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GENB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.64%📐 HORIZONTAL RANGE
2026-11-03O $15.77H $15.77L $13.21C $13.21VOL 1.17M
RES: $26.76SUP: $10.82SMA50: $14.92SMA200: $14.08
$23.43$20.29$17.15$14.01$10.87RES $26.76SUP $10.82$13.212026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GENB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GENB Butterfly Map → + Track GENB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GENB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GENB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GENB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GENB)

Health Care Rank #241 of 1015 ⚔️ ZBIO vs GENB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GENB vs. ZBIO, AGIO, TRAX, ADRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Generate Biomedicines Inc. (GENB) ranks #241 by composite RQD confidence (52/100, grade D+) and #268 by equity capitalization ($1.86B). Within this direct 5-issuer industry benchmark cohort, GENB leads on earnings valuation at N/A trailing P/E, while AGIO leads on capital efficiency and profitability with -33.8% ROIC and 88.3% gross margin. GENB currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GENB ACTIVE
Generate Biomedicines Inc.
D+ 52/100 — — — -8.64% $1.86B Benchmark Subject
ZBIO
Zenas BioPharma Inc.
D- 38/100 — — -35.0% -2.71% $1.85B /zbio-vs-genb →
AGIO
Agios Pharmaceuticals Inc.
D- 35/100 — 88.3% -33.8% -1.96% $1.82B /agio-vs-genb →
TRAX
First Tracks Biotherapeutics Inc.
D 44/100 — — -35.0% -0.07% $1.89B /trax-vs-genb →
ADRX
ADARx Pharmaceuticals Inc.
D 48/100 — — — -7.29% $1.82B /adrx-vs-genb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002100782 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Generate Biomedicines Inc. (GENB) reported GAAP revenue of $138.7M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, GENB closed FY2025 with $330.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $138.7M $0 — — $330.2M —

3. GENB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GENB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Generate Biomedicines Inc. (NASDAQ: GENB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $13.21 (-8.64% 1D, market cap $1.86B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

How does GENB compare to ZBIO and AGIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GENB carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ZBIO (Zenas BioPharma Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B) and AGIO (Agios Pharmaceuticals Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -33.8%, cap $1.82B). Among the 5-stock peer group, GENB leads on earnings multiple (N/A) while AGIO leads on capital efficiency (-33.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GENB?

Per GENB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002100782), Generate Biomedicines Inc. generated $138.7M in revenue, $0 in net income, and $0 in free cash flow against $330.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GENB trading relative to its 50-day, 200-day, and 52-week technical levels?

GENB last traded at $13.21 (-8.64% on volume of 745,463 shares), positioning the stock -11.46% below its 50-day simple moving average ($14.92) and -6.18% below its 200-day simple moving average ($14.08). Across its 52-week range of $11.00 to $22.67, GENB sits at the 18.9% percentile with a 14-day RSI of 51.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.56 to $14.86).

Direct Sub-Reports: GENB RQD Cockpit GENB 12M Forecast GENB Earnings & Move GENB Dividends & DRIP GENB Insiders & 13F GENB Whale Options GENB Profit Sankey GENB News & Why
ROARABLE RATING BRIEF • RQD 52/100 (D+) ✓ SEC XBRL & RQD VERIFIED

GENB — Generate Biomedicines Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Generate Biomedicines Inc. (GENB) earns a live Roarable RQD composite score of 52/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $13.21 (-8.64% 1D, market capitalization $1.86B).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Generate Biomedicines Inc. (GENB) is a NASDAQ-listed operating company in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity market capitalization of $1.86B. The business operates with a gross margin of 0%, an operating margin of 0%, and a return on invested capital (ROIC) of 0% (free cash flow yield of 0%). Within the Biotechnology: Pharmaceutical Preparations peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Generate Biomedicines Inc. (GENB) reported $138.7M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $330.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 52/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $11.00 – $22.67 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level linkage is the liquidity signal above: a 3.73x beta to Net Liquidity means GENB's price is expected to be highly sensitive to shifts in Fed balance-sheet, Treasury General Account, and reverse-repo flows. A second-order watch item is that a tightening in these liquidity inputs would, per the signal's own framing, pressure the stock disproportionately relative to a 1.0 market beta.

  • Key Question #1: Can GENB sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $138.7M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is GENB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GENB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Generate Biomedicines Inc. (GENB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GENB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GENB Bull vs. Bear Conversation Board — What's Your Call at $13.21?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GENB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GENB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $17.21 (+19.0%)
📌 Pinned Debate

Up to nearly $1.2B in milestones tied to planned AI obesity-drug research could provide future revenue visibility not reflected in curr

Don't sleep on GENB's setup in Health Care. Up to nearly $1.2B in milestones tied to planned AI obesity-drug research could provide future revenue visibility not reflected in current financials.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (52/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

Both sides have a point here — GENB's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $11.28 (-22.0%)
Spot @ $14.46

Zero reported revenue, zero ROIC, and a bearish 3.73x liquidity elasticity signal leave the stock exposed to both fundamental and macro

Here is the bear case nobody on the bull side wants to address on GENB: Zero reported revenue, zero ROIC, and a bearish 3.73x liquidity elasticity signal leave the stock exposed to both fundamental and macro downside.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%